BVXP Bioventix PLC

LSE · GB · Healthcare · Biotechnology · bioventix.com

1685.00GBp+0.60%Mkt Cap: 95.69M $P/E: 11.95Today

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertilit…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap95.69M USD

Enterprise Value89.36M USD

Revenue (TTM)13.63M USD

Gross Profit12.95M USD

Net Income (TTM)8.24M USD

Revenue/Share2.40 GBp

Last Price1685.00 GBp

Fiscal Year EndJun 2025

MR QuarterDec 2025

Employees12

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)11.95

P/E (Forward)0.09

PEG—

EV/EBITDA8.36

EV/Revenue6.55

P/S6.98

P/B7.93

EPS (TTM)1.41

EPS (Forward)179.30

52W Range

0.000066% of range2550.00

52W High2550.00 GBp

52W Low0.0000 GBp

Profitability

Gross Margin90.86%

Oper. Margin76.56%

EBITDA Margin78.45%

Profit Margin57.83%

ROE65.66%

ROA58.96%

Growth

Revenue Growth-8.50%

Earnings Growth-3.90%

Cash Flow & Leverage

Operating CF7.64M USD

CapEx (TTM)20.86K USD

FCF Margin52.59%

FCF Yield7.49%

Net Debt-5.77M USD

Net Debt/EBITDA-0.54

Balance Sheet

Debt/Equity—

Current Ratio6.12

Quick Ratio5.76

Book Value/Sh2.11 GBp

Cash/Share1.01 GBp

Dividends

Fwd Div Rate1.50 GBp

Trail. Div Rate1.50 GBp

Div. Yield8.96%

5Y Avg Yield4.21%

Payout Ratio106.75%

Ex-Div DateApr 9, 2026

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)3900.00 GBp

Upside (mean)+131.5%

Target Range3900.00 GBp – 3900.00 GBp

# Analysts1

Ownership

Shares Out.5.22M

Float4.15M

Insiders7.70%

Institutions59.99%

Technical

SMA 501602.10 (+5.2%)

SMA 2001653.65 (+1.9%)

Beta0.56

S&P 52W Chg14.58%

Avg Vol (30d)10.93K

Avg Vol (10d)10.13K

Technical Indicators

RSI (14)57.1

MACD10.7248

MACD Signal-1.1535

MACD Hist.+11.8783

BB Upper1753.37 GBp

BB Middle1604.75 GBp

BB Lower1456.13 GBp

BB Width18.52%

ATR (14)121.52 GBp

Vol Ratio (20d)1.09x